Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Slow-Drip ketamine may ease pain with fewer weird side effects

NCT ID NCT05518877

Symptom relief Sponsor: Summa Health System Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving a low dose of ketamine over 30 minutes instead of 15 minutes could reduce side effects like dizziness or hallucinations while still controlling acute pain. 55 adults with severe pain in the emergency department took part. The goal was to find a better balance between pain relief and unwanted effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ketamine
What this could lead to
If successful, this could lead to a safer way to give ketamine for acute pain in the emergency room, with fewer side effects like dizziness or hallucinations.
What could go wrong
This is a small, early-phase trial with only 55 participants. The results may not apply to all patients or settings, and side effects may still occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

55 people

The number who actually took part.

Started

Dec 2022

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 110 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Patients aged 18 or older * Primary complaint of acute moderate to severe pain on VAS/ numeric pain scale (a score of ≥5cm which corresponds to 50mm). * Pain described as abdominal, flank, back, musculoskeletal, or traumatic chest pain * Must be alert and oriented times three * Able to provide consent Exclusion criteria: * Pregnant * Breastfeeding * Altered mental status * Known or reported allergy, hypersensitivity or intolerance to ketamine * Unstable vital signs (systolic blood pressure \<80 or \>180mmHg, heart rate \<50 or \>150 beats per minute, and respiratory rate \<10 or \>30 breaths per minute) * History of unstable heart disease, such as arrhythmias, congestive heart failure, or coronary heart disease. * History of untreated or uncontrolled thyroid disease * Acute head or eye injury * Active or current use of alcohol or drugs * Known intracranial hypertension * Hepatic or renal insufficiency * Current active manic phase of bipolar disorder * Active delusions, hallucinations, or schizophrenia * Patients who have recent fentanyl use within 60 minutes or other analgesic use (opiates) within 4 hours of study enrollment (signing of consent) * Patients who have enrolled in the study during a previous ED encounter * Chronic use of opiates (i.e.: fentanyl patch, SR opiates)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dissociation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Acute Pain dissociative disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dissociation Pain, acute

Contacts and locations

Locations

  • Summa Health System

    Akron, Ohio, 44304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.